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association with productivity measures. METHODS: A cross-sectional survey of 
adults diagnosed with T2DM on OADs, and not insulin, was conducted. A list of 
common tolerability issues from OAD prescribing information was provided; experi-
ence with each was asked in the survey. The Diabetes Productivity Measure (DPM)
and the Work Productivity and Activity Impairment (WPAI) measure work productiv-
ity. Chi-square tests were done for categorical variables and t-tests for continuous 
variables. Linear-regression methods were used to control for respondent characteris-
tics. RESULTS: Of 2,074 survey respondents, 53% were men and mean age was 
60 yrs (SD  10.83). In the 2 wks preceding the survey, 70.5% experienced at least
one tolerability issue. The most commonly reported issues were hypoglycemia (57.2%,
q1 symptom), constipation or diarrhea (28%), headaches (26%), and water retention
(21%). In most cases, a reduction in work productivity of 8% to 24%, mainly impair-
ing work presenteeism, was observed with tolerability issues reported in the previous
two weeks (WPAI: p  0.05). After adjusting for characteristics, signiﬁ cant reductions 
on productivity, measured by DPM and WPAI (p  0.05), were observed for hypogly-
cemia (9.7% to 10.6%), unintended weight loss (11.1% to 14.4%), water reten-
tion (3.6% to 4.9%), constipation or diarrhea (2.8% to 4.2%) and urinary 
tract infection (13.5% to 16.8%). Cardiovascular events were signiﬁ cant (67%,
p  0.05) with WPAI, but not DPM; nausea/vomiting, headache, genital infections, 
and appetite loss were not signiﬁ cant. CONCLUSIONS: T2DM patients reported a
high level of tolerability issues and diabetes symptoms associated with decreased work 
productivity. This study highlights the importance of addressing tolerability issues and 
symptoms to reduce overall disease burden.
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OBJECTIVES: A considerable amount of the investigation of geographic variation 
focuses on Medicare data and excludes prescription drugs. This study focuses on pre-
scription medications used to treat chronic conditions in the commercial sector and
incorporates demand-side information on insurance beneﬁ t design (e.g., patient cost-
sharing) to analyze variations in adherence. METHODS: Patients age 18–64 in
employer-sponsored plans with at least two years of continuous medical and prescrip-
tion coverage meeting diagnostic criteria for diabetes were found in the MarketScan 
Database (n  449,127). Medication Possession Ratios (MPRs) were calculated in
2006 and 2007 for four classes of medications (antidiabetic medications, statins, ACE 
Inhibitors, Angiotensin II Receptor Blockers (ARB)) for each patient with at least 
one prescription within the class each year. Multivariate logistic regressions of poor 
adherence (MPR  80%) were estimated to adjust for patient, employer, beneﬁ t plan, 
provider supply, and area (e.g., income, unemployment) characteristics. Expected 
adherence based on predicted values from the multivariate regressions was aggregated 
to the geographic area (hospital referral region, HRR) level and the ratio of observed 
to expected adherence was computed along with the 95% conﬁ dence interval of the
ratio. RESULTS: Across HRRs the median rate of subobtimal antidiabetic medication 
adherence was 32.3% of patients, rates in HRRs varied from 19.2% to 54.6%. The 
median rate was 44% for ACE Inhibitors (range 30.2% to 60.4%), 43.9% for ARBs
(range 27.5% to 60.7%) and 59.3% for statins (range 45% to 74.5%). The difference 
between observed and expected adherence was statistically signiﬁ cant for 8.9% of 
HRRs for antidiabetic medication, 9.1% of HRRs for ACE Inhibitors, 6.7% of HRRs 
for ARBs and 1.3% of HRRs for statins (p  0.05). CONCLUSIONS: Observed
market level traits such as provider supply and unemployment explain some of the 
variation in adherence. After adjusting for covariates, geographic variation in chronic
condition medication utilization remains.
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OBJECTIVES: A randomized controlled study is being conducted to evaluate 2 types
of educational interventions (groups using Conversation Maps, versus individual)
compared to usual care (no educational intervention) for patients with pre-existing
type-2 diabetes and suboptimal glycemic control (A1c  7%). The purpose is to 
determine if there are correlations at baseline with patient Readiness to Change (RTC) 
and attitudes toward diabetes, and measures of general health and diabetes control. 
METHODS: At baseline, 167 female and 172 male patients (mean age 63 years, mean
A1c 8.1) enrolled in the Merck-funded Journey for Control of Diabetes IDEA Study 
and completed a baseline survey. Validated instruments embedded in the survey were:
RTC (O’Connor et al, 2004), functional health status (SF-12), attitude towards dia-
betes (positive attitude and care ability scales, sections of the Diabetes Care Proﬁ le
from Michigan Diabetes Research and Training Center). Also, the most recent A1c 
result within the last six months and length of time diagnosed with diabetes were
obtained. RESULTS: Pearson correlations were used to assess associations between
RTC and general health, diabetes attitudes, and measures of diabetes control. Mean 
RTC scores were 24.02 (range 7 – 38; n  320), with females slightly more ready to 
change than males (p  0.0924). RTC had a signiﬁ cant positive correlation with 
A1c (r  0.1096, p  0.0500), with both the number of reported hypoglycemic events 
(r  0.16217, p  0.0037) and hyperglycemic events (r  0.13854, p  0.0133). RTC 
was also signiﬁ cantly correlated with Positive Attitudes toward diabetes (r  0.11415, 
p  0.0433). Interestingly, RTC was not related to functional health (r  0.10964, 
p  0.7167). CONCLUSIONS: RTC is a useful tool to identify the potential success
for diabetes education. Additional validation of this ﬁ nding will be available upon the 
conclusion of the study.
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OBJECTIVES: To determine diabetes control status among community pharmacy
users with diabetes. METHODS: This is a cross-sectional observational study analyz-
ing the Medical Expenditure Panel Survey (2005), a survey nationally representative 
of non-institutionalized civilians. The study population was community pharmacy
users older than 17 with diabetes. Using a chi-square test, this study compared the 
proportions of the study population with complications and without complications 
meeting the diabetes control standards of the American Diabetes Association (ADA).
A logistic regression was employed to compare between the 2 groups the likelihood
of incurring drug costs over $4000 in 2006 dollars, the cost criterion for being eligible 
for mediation therapy management (MTM) services. Community pharmacies were 
deﬁ ned as pharmacies other than mail-order and online pharmacies. RESULTS: In 
2005, 95.27% of patients with diabetes ﬁ lled prescriptions through community phar-
macies. There were gaps between their diabetic control and the ADA standards, espe-
cially in the use of preventive services: e.g., ADA recommends weight control, but the
proportions of overweight or obese were 84.09% and 89.42% among patients without 
complications and those with complications, respectively (P  0.312 for the group
comparison). Patients with complications have higher likelihood of meeting the cost
criterion for MTM services even after adjusting for confounding factors (P  0.005). 
CONCLUSIONS: The room for improvements in diabetes control among community 
pharmacy users in this study present pharmacists with opportunities for improving
diabetes management.
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OBJECTIVES: To describe the relationship between A1c levels and medication
possession ratio (MPR) of three oral anti-hyperglycemic medications (sulfonylureas,
biguanides and thiazolidinediones) for participants enrolled in a diabetes disease 
management program. METHODS: This was a retrospective evaluation of partici-
pants enrolled in a diabetes disease management program. Continuously enrolled
participants were included if there was a documented A1c value. The MPR was cal-
culated from administrative pharmacy claims data. Participants were classiﬁ ed as low, 
moderate or high risk based on their A1c levels. ANOVA was used to analyze differ-
ences in mean MPR between the three groups. For participants on more than one drug
class, a Pearson’s correlation was used to analyze relationship of MPRs between dif-
ferent drug classes. RESULTS: A total of 57 percent of participants on sulfonylurea
therapy, 64 percent of participants on biguanides and 63 percent of those on thiazoli-
dinediones reached an A1c goal of 7. Participants classiﬁ ed as high risk (A1c  9) 
had a lower MPR compared to participants in the low and moderate risk group (p 
0.0001). For participants taking a sulfonylurea, the mean MPR for those who reached 
the predetermined A1c goal (7) was 0.89 (o0.21) compared with 0.76 (o0.30) for 
those in the high risk group (p  0.001). MPR for thiazolidinediones was 15 percent 
lower in participants with A1c  9 (p  0.001). Pearson correlation analysis showed 
a positive relationship between the MPRs in different drug classes. CONCLUSIONS:
Medication adherence as measured by the MPR was higher for participants who
reached the target A1c goal of 7.
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OBJECTIVES: Tight glycemic control of diabetic patients yields both clinical and 
ﬁ nancial beneﬁ ts. Despite recommendations for HbA1C testing to assess the effective-
ness of management plans on glycemic control, achieving adherence to recommenda-
tions for frequency of HbA1C testing continues to be a challenge. When prior 
authorization (PA) was required in the Leumit Health Fund of Israel for expensive
diabetes medications, requests for these drugs were not reviewed until the patient had
performed an HbA1C test (one test within the previous four months). This policy 
induced complete adherence to recommendations for testing amongst patients treated
